

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/725,629	12/01/2003	Pierre Beuparlant	9988-012-999

20583  
 JONES DAY  
 222 EAST 41ST ST  
 NEW YORK, NY 10017

CONFIRMATION NO. 4706

## FORMALITIES LETTER



\*OC000000013507170\*

Date Mailed: 08/11/2004

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted***Items Required To Avoid Abandonment:**

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

10/28/2004 MBLANCO 00000004 503013 10725629

01 FC:1051 130.00 DA

patin21help@uspto.gov or patin3help@uspto.gov

**SUMMARY OF FEES DUE:**

Total additional fee(s) required for this application is **\$130** for a Large Entity

- **\$130** Late oath or declaration Surcharge.

Replies should be mailed to:    Mail Stop Missing Parts  
   Commissioner for Patents  
   P.O. Box 1450  
   Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

Meaza W  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



10-27-04

#/DPW

Express Mail No.: EV 475 141 277 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Pierre Beauparlant *et al.*

Confirmation No.: 4706

Serial No.: 10/725,629

Art Unit: 1614

Filed: December 1, 2003

Examiner: To be assigned

For: DITERPENOID COMPOUNDS,  
COMPOSITIONS THEREOF AND THEIR  
USE AS ANTI-CANCER OR ANTI-  
FUNGAL AGENTS

Attorney Docket No.: 9988-012-999

**RESPONSE TO NOTICE TO FILE  
MISSING PARTS OF NONPROVISIONAL APPLICATION**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to File Missing Parts of Nonprovisional Application ("Notice") mailed August 11, 2004, a copy of which is attached hereto, Applicants submit herewith a Declaration for Non-Provisional Patent Application executed by Pierre Beauparlant on October 6, 2004, Giorgio Attardo on October 6, 2004, Zhiying Zhang on September 30, 2004, Jean-Francois Lavallee on September 30, 2004, Sasmita Tripathy on September 30, 2004, Samuel Fortin on October 6, 2004, Angela M. Stafford on October 5, 2004, Rosa Ubillas on October 11, 2004, and James B. McAlpine on October 4, 2004.

A Petition for Extension of Time for 1 month from October 11, 2004 to November 11, 2004 is also enclosed.

Under separate transmittal, Applicants submit herewith a paper copy and a computer readable copy of the sequence listing accompanied by a statement that the content of the sequence listing in computer readable form is identical to the content of the paper copy of the sequence listing.

An Assignment of the above-identified application to Gemin X Biotechnologies Inc. is concurrently submitted under separate cover to the Assignment Recordation Services for recordation. A copy of the Assignment is also enclosed. Also submitted herewith is a Power of Attorney by Assignee and Exclusion of Inventors executed by Dan A. Giampuzzi, President and Chief Executive Officer of Gemin X Biotechnologies, Inc., on October 21, 2004, on behalf of Gemin X Biotechnologies Inc., assignee of the above-identified application. Mr. Giampuzzi is authorized to act on behalf of the assignee Gemin X Biotechnologies Inc.


An Assignment of the above-identified application to Galileo Pharmaceuticals, Inc. is concurrently submitted under separate cover to the Assignment Recordation Services for recordation. A copy of the Assignment is also enclosed. Also submitted herewith is a Power of Attorney by Assignee and Exclusion of Inventors executed by Dr. Guy Miller, Chairman and Chief Executive Officer of Galileo Pharmaceuticals, Inc., on October 19, 2004, on behalf of Galileo Pharmaceuticals, Inc., assignee of the above-identified application. Dr. Miller is authorized to act on behalf of the assignee Galileo Pharmaceuticals, Inc.

It is requested that the enclosed documents be made of record in the file of the above-identified application.

The fee for this submission is believed to be \$130.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013. Should any additional fee be required in connection with the present response, the commissioner is hereby authorized to charge any such additional fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: October 26, 2004

  
\_\_\_\_\_  
Laura A. Coruzzi  
JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

30,742  
(Reg. No.)

Enclosures